Remarkable tumor shrinkage in hilar biliary cholangiocarcinoma confirmed by peroral cholangioscopy following neoadjuvant chemotherapy
Endoscopy · 01.12.2024 · 56 (S 01 S 01) · E85-E86
DOI: 10.1055/a-2234-4355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.12.2024. Verfasst von Ko Tomishima und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Klatskin Tumor, Bile Duct Neoplasms. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Department of Human Pathology, Juntendo University School of Medicine, Tokyo, Japan.
ORCID-Profile: Toshio Fujisawa, Hiroyuki Isayama
Zitieren
APA
Tomishima, K., Suzuki, A., Ito, K., Ishii, S., Fujisawa, T., Fukumura, Y., & Isayama, H. (2024). Remarkable tumor shrinkage in hilar biliary cholangiocarcinoma confirmed by peroral cholangioscopy following neoadjuvant chemotherapy. Endoscopy, 56(S 01 S 01), E85-E86. https://doi.org/10.1055/a-2234-4355
Vancouver
Tomishima K, Suzuki A, Ito K, Ishii S, Fujisawa T, Fukumura Y, et al. Remarkable tumor shrinkage in hilar biliary cholangiocarcinoma confirmed by peroral cholangioscopy following neoadjuvant chemotherapy. Endoscopy. 2024;56(S 01 S 01):E85-E86. doi:10.1055/a-2234-4355
BibTeX
@article{Tomishima2024,
author = {Tomishima, Ko and Suzuki, Akinori and Ito, Koichi and Ishii, Shigeto and Fujisawa, Toshio and Fukumura, Yuki and Isayama, Hiroyuki},
title = {Remarkable tumor shrinkage in hilar biliary cholangiocarcinoma confirmed by peroral cholangioscopy following neoadjuvant chemotherapy},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 01 S 01},
pages = {E85--E86},
doi = {10.1055/a-2234-4355}
}
EUVIMED